# Syndexa Pharmaceuticals Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/syndexa-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Watertown, US
- Website: www.syndexa.com
- Latest round: Series B (Dec 30, 2011)
- Investors on record: 1

## About

Syndexa Pharmaceuticals Corporation operates in the pharmaceutical sector, focusing on the development and commercialization of innovative therapies to address unmet medical needs.Formed in 2005, Syndexa Pharmaceuticals Corporation is based in Watertown, US, and specializes in pharmaceutical development. The company has successfully completed 4 funding deals, with the latest being a Series B round that raised USD 15.00 mn, bringing the total amount raised to USD 15.00 mn.Syndexa.com primarily offers a domain name for sale, specifically the URL "Syndexa.com." The core service revolves around facilitating the purchase and transfer of this domain name, providing a secure and straightforward transaction process for buyers. This service is designed to cater to businesses or individuals looking to establish an online presence or brand identity through a unique and memorable web address. The target clientele includes entrepreneurs, small to medium-sized enterprises, and established brands seeking to enhance their digital footprint. The domain is available for potential buyers globally, with dedicated 24/7 customer support ensuring that clients receive assistance throughout the purchase process.Syndexa.com generates revenue through the sale of its domain name, with transactions structured as direct purchases made by interested clients. The company utilizes a straightforward pricing model where buyers pay a fixed price for the domain, facilitating a seamless transaction experience. The business caters to various customer segments, including businesses and individuals looking to acquire a significant online asset. Payments are made upfront, and the transfer process is completed promptly to ensure client satisfaction.Syndexa Pharmaceuticals Corporation has identified strategic initiatives for future growth, including the launch of new products designed to expand its portfolio. The company is planning to enter new markets in the pharmaceutical sector, specifically targeting regions in North America and Europe by 2025. Recent funding from the Series B round will support these growth initiatives and enhance research capabilities.

## Funding rounds

- Series B, Dec 30, 2011 — MP Healthcare Venture Management

## Investors

- MP Healthcare Venture Management (https://capitalatlas.ai/funds/mp-healthcare-venture-management) — Series B